Bicycle Therapeutics (BCYC) Operating Leases (2019 - 2026)

Bicycle Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $13.9 million for Q1 2026.

• Quarterly Operating Leases rose 431.77% year-over-year to $13.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.9 million (up 431.77% YoY) and the FY2025 annual result came in at $14.1 million, up 253.28% from the prior year.
• Operating Leases was $13.9 million for Q1 2026 at Bicycle Therapeutics, down from $14.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $14.4 million in Q1 2023 and bottomed at $981000.0 in Q3 2025.
• A 5-year average of $9.0 million and a median of $10.4 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2025 — Operating Leases plunged 82.27% — and 2026, when it surged 431.77%.
• Bicycle Therapeutics' Operating Leases stood at $10.9 million in 2022, then slipped by 13.81% to $9.4 million in 2023, then slumped by 57.47% to $4.0 million in 2024, then jumped by 253.28% to $14.1 million in 2025, then decreased by 1.57% to $13.9 million in 2026.
• Business Quant data shows BCYC's Operating Leases at $13.9 million in Q1 2026, $14.1 million in Q4 2025, and $981000.0 in Q3 2025.